SAB Biotherapeutics, Inc.
SABS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 87 institutions reported holding it in 13F filings for Q2 2026, worth $266.8M in total; no superinvestor holds it.
Other share classesSABSW
Q4 2022 vs. Q3 2022
How the institutions holding SAB Biotherapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 40 | 2 | 38 | 0 |
| Shares | 3.31M | 22.5K | 4.09M | +807.8K (+24.6%) |
| Value | $2.32M | $16.2K | $2.42M | +$113.1K (+4.9%) |
2 institutions that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (8)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Warberg Asset Management LLC | 370,370 | $218.5K | 0.07% |
| HighTower Advisors, LLC | 75,970 | $44.0K | 0.00% |
| Silver Oak Securities, Inc | 51,941 | $31.0K | 0.01% |
| Nadler Financial Group, Inc. | 13,750 | $8.11K | 0.00% |
| Susquehanna International Group, LLP | 11,441 | $6.75K | 0.00% |
| Baird Financial Group, Inc. | 10,000 | $6.00K | 0.00% |
| Money Concepts Capital Corp | 250 | $147 | 0.00% |
| GWM Advisors LLC | 145 | $0 | 0.00% |
Sold out (8)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Millennium Management LLC | 38,547 | $27.0K |
| Jane Street Group, LLC | 23,954 | $17.0K |
| Goldman Sachs Group Inc | 12,618 | $9.00K |
| FMR LLC | 9,000 | $6.00K |
| Wolverine Asset Management LLC | 3,926 | $2.00K |
| Citigroup Inc | 494 | $0 |
| Daiwa Securities Group Inc. | 127 | $0 |
| China Universal Asset Management Co., Ltd. | 403 | $0 |
Not filed for Q4 2022 yet (2)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| American Portfolios Advisors | 17,466 | $12.2K |
| Spectrum Management Group, LLC | 5,030 | $4.00K |